Drug Profile
XR 304
Latest Information Update: 28 Jul 2004
Price :
$50
*
At a glance
- Originator Xenova Group
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Ulcerative colitis
Most Recent Events
- 27 Jul 2004 Discontinued - Preclinical for Ulcerative colitis in United Kingdom (unspecified route)
- 11 Nov 2003 Preclinical trials in Ulcerative colitis in United Kingdom (unspecified route)